Significant backlash. It has been announced that a joint research agreement on biomarker analysis of specimen samples has been concluded with Tohoku University as an additional analysis of a phase 2 clinical trial (physician-led clinical trial) in which recombinant human HGF protein preparations are administered to patients with amyotrophic lateral sclerosis (ALS). Biomarkers of neurodegeneration and neuroinflammation are measured on specimen samples obtained in clinical trials to verify the effects of HGF administration, and it is expected that important information such as identifying patient groups that are easy to detect effects can be obtained.
クリングル---大幅に反発、ALS対象臨床試験の追加解析で東北大と共同研究、バイオマーカー解析
Kringle --- significant backlash, joint research with Tohoku University in additional analysis of clinical trials targeting ALS, biomarker analysis
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.